Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (336)	8/17/2001 2:28:03 AM
From: tuck	Read Replies (1) \| Respond to of 1005

FWIW, an upcoming opportunity to get virtually up close and personal with SGEN: >>BOTHELL, Wash.--(BW HealthWire)--Aug. 16, 2001--Seattle Genetics, Inc. (Nasdaq:SGEN - news) company management will host a business update meeting on August 21, 2001 at approximately 3:45 p.m. Pacific Time. The session will include presentations on research, development and clinical trial activities. Scheduled presenters include H. Perry Fell, Ph.D., Chief Executive Officer, Clay B. Siegall, Ph.D., President and Chief Scientific Officer and Tim Carroll, Chief Financial Officer. A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the ``News and Investor Information/audio presentations'' section. About Seattle Genetics Seattle Genetics discovers and develops monoclonal antibody, or mAb, -based therapeutics to treat cancer and related diseases. The Company has four technologies: engineered mAbs, mAb-drug conjugates, single-chain immunotoxins and antibody-directed enzyme prodrug therapy (ADEPT). Seattle Genetics has built a diverse portfolio of drug candidates targeted to many types of human cancers, including two currently being tested in clinical trials. The Company also out-licenses its mAb-based technologies to strategic partners developing targeted therapies. Seattle Genetics has agreements with many organizations including Genentech, Medarex, Aventis, Bristol-Myers Squibb, Eos Biotechnology, Arizona State University, the University of Miami, and CLB Research and Development. More information about Seattle Genetics can be found at www.seattlegenetics.com. -------------------------------------------------------------------------------- Contact: Seattle Genetics Manager of Investor Relations Peggy Pinkston, 425/527-4160 ppinkston@seagen.com<< Cheers, Tuck